Evidence map›Paper›PMID 33206382›Full record

Trial reportDevelopmental medicine and child neurology2021

Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat-treatment study.

Mauricio R Delgado, Ann Tilton, Jorge Carranza-Del Río, Nigar Dursun, Marcin Bonikowski, Resa Aydin, Iwona Maciag-Tymecka, Joyce Oleszek, Edward Dabrowski, Anne-Sophie Grandoulier and 2 more

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Developmental medicine and child neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02106351 phase3completednot on this map

A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT® Used In The Treatment Of Upper Limb Spasticity In Children

TypeinterventionalSponsorIpsenRan2014 to 2018Enrolled212ConditionsUpper Limb Spasticity (Altered Skeletal Muscle Performance) in ChildrenArmsBotulinum toxin type A
NCT06128616 phase3unknown statusnot on this mapstarted 2023, after this paper: background citation

Efficacy of Extracorporeal Shock Wave Therapy Integrated to Combined Treatment of Botulinum Toxin A and Serial Casting in Children With Cerebral Palsy

TypeinterventionalSponsorKocaeli UniversityRan2023 to 2024Enrolled40ConditionsSpasticity/Paresis, Cerebral PalsyArmsESWT, Botulinum Toxin Type A, Serial Casting, Physical Therapy, Occupational Therapy
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. The state of the art in therapeutic administration of botulinum toxin in children with cerebral palsy: an integrative review.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 6 countries.

Mauricio R DelgadoDepartment of Neurology, University of Texas Southwestern Medical Center, Scottish Rite Hospital for Children, Dallas, TX, USA.ORCID 0000-0003-1855-8654
Ann TiltonDepartment of Neurology, LSUHSC and Children's Hospital New Orleans, New Orleans, LA, USA.
Jorge Carranza-Del RíoHospital San José Celaya, Celaya, Guanajuato, Mexico.
Nigar DursunDepartment of Physical Medicine and Rehabilitation, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.ORCID 0000-0002-6552-7204
Marcin BonikowskiMazovian Neuropsychiatry Center, Zagórze, nr Warsaw, Poland.
Resa AydinDepartment of Physical Medicine and Rehabilitation, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Iwona Maciag-TymeckaRehabilitation Center KROK PO KROKU, Gdansk, Poland.
Joyce OleszekDepartment of Physical Medicine and Rehabilitation, University of Colorado and Children's Hospital Colorado, Aurora, CO, USA.
Edward DabrowskiDepartment of Pediatric Physical Medicine and Rehabilitation, Beaumont Health, Oakland University School of Medicine, Grosse Pointe, MI, USA.
Anne-Sophie GrandoulierAtlanstat consultant for Ipsen Pharma, Les Ulis, France.
Philippe PicautIpsen Pharma, Cambridge, MA, USA.
Dysport in PUL study group
Ipsen (France) · FRChildren's Hospital Colorado · USChildren's Hospital of New Orleans · USIstanbul University · TRKocaeli Üniversitesi · TRKowa (United Kingdom) · GBNeuro Device (Poland) · PLOakland University · USTexas Scottish Rite Hospital for Children · USUniversity of Celaya · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP).

methodThis was a double-blind, repeat-cycle study (NCT02106351) in children with CP (2-17y). Children were randomized to receive 2U/kg (control), 8U/kg, or 16U/kg abobotulinumtoxinA injections into the target muscle group (wrist or elbow flexors) and additional muscles alongside occupational therapy via a home-exercise therapy program (HETP; minimum five 15min sessions/wk). Children received 8U/kg or 16U/kg plus HETP in cycles 2 to 4.

resultsDuring cycle 1, 210 children (126 males, 84 females; mean age [SD] 9y [4y 5mo], range 2-17y; n=70/group) had at least one upper limb abobotulinumtoxinA injection and 209 complied with the HETP. At week 6 of cycle 1, children in the 8U/kg or 16U/kg groups had significantly lower Modified Ashworth scale scores versus the 2U/kg group (primary outcome: treatment differences of -0.4 [p=0.012] and -0.7 [p<0.001] respectively). All groups improved on Physician Global Assessment and children in all groups achieved their treatment goals at least as expected. Therapeutic benefits were sustained during cycles 2 to 4; muscular weakness was the only treatment-related adverse event reported in at least one child/group (4.3% and 5.7% vs 1.4% respectively).

interpretationTreatment with 8U/kg or 16U/kg abobotulinumtoxinA significantly reduced upper limb spasticity versus the 2U/kg control dose. Therapeutic benefits of abobotulinumtoxinA plus HETP were sustained with repeat treatment cycles. WHAT THIS PAPER ADDS: AbobotulinumtoxinA injections significantly reduced upper limb spasticity in children with cerebral palsy. Children treated with abobotulinumtoxinA and targeted home exercises showed global improvement and goal attainment. Benefits were sustained over 1 year with repeat cycles of abobotulinumtoxinA and home exercises. AbobotulinumtoxinA injections into the upper limb were well tolerated over 1 year.

Indexed as

AdolescentBotulinum Toxins, Type ACerebral PalsyChildChild, PreschoolDouble-Blind MethodFemaleHumansInjections, IntramuscularMaleMuscle SpasticityNeuromuscular AgentsTreatment OutcomeUpper ExtremityabobotulinumtoxinABotulinum Toxins, Type ANeuromuscular Agents

Identifiers

PMID33206382
PMCPMC8048784
OpenAlexW3099415617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.